Celgene (CELG): Clinical CELMoD Data Creates LT Optionality - BMO

BMO Capital analyst, Ian Somaiya, reiterated his Outperform rating on Celgene (NASDAQ: CELG) after the company unveiled clinical data from its CELMoD pipeline, showcasing its expertise in protein homeostasis.

The near-term impact on CELG shares is expected to be limited but the pipeline optionality from 2020-30 could be meaningful. Promising early clinical results from ongoing trials of CC-122 in DLBCL and CC-220 in Lupus highlighted the company’s knowledge of Cereblon and the use of biomarker and PD data to drive efficacy.

The analyst believes CC-220 could be ideally suited for myeloma but the drug’s success in an ongoing lupus trial could also lead to Celgene pursuing a back-up compound.

No change to the price target of $141.

For an analyst ratings summary and ratings history on Celgene click here. For more ratings news on Celgene click here.

Shares of Celgene closed at $102.77 yesterday.

You May Also Be Interested In

• AXIS Capital (AXS) PT Lowered to $108 at BMO Capital
• JPMorgan Downgrades Pirelli & Co (PIRC:IM) (PLLIF) to Neutral
• Eicher Motors (EIM:IN) PT Raised to INR9,100 at UBS